HCV RNA detection in HCV antibody-positive patients with the COBAS® AmpliPrep/COBAS® TaqMan® HCV test, v2.0 in comparison with FDA-approved nucleic acid tests

Journal of Clinical Virology

Volumn 60, Issue 4, 2014, Pages 336-340

  Butcher, Ann ^a   Aslam, Shagufta ^a   Hemyari, Pari ^a   Cowen, Ula ^a   Heilek, Gabrielle ^a  

^a ROCHE MOLECULAR SYSTEMS   (United States)

Author keywords

Hepatitis C virus; Limit of detection; Nucleic acid testing; Sustained virologic response

Indexed keywords

ANTIVIRUS AGENT; DIAGNOSTIC KIT; VIRUS RNA; EDETIC ACID; HEPATITIS C ANTIBODY; HEPATITIS C VIRUS RNA; UNCLASSIFIED DRUG;

ADULT; BLOOD; COMPARATIVE STUDY; DIAGNOSTIC KIT; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMAN; LIMIT OF DETECTION; MALE; MOLECULAR DIAGNOSIS; POLYMERASE CHAIN REACTION; PROCEDURES; VIRUS LOAD; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; NUCLEIC ACID ANALYSIS;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIMIT OF DETECTION; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; VIRAL LOAD;

EID: 84903585375     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.04.018     Document Type: Article

References (29)

1. Lauer G.M., Walker B.D. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
2. Armstrong G.L., Wasley A., Simard E.P., McQuillan G.M., Kuhnert W.L., Alter M.J. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
3. Te H.S., Jensen D.M. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010, 14. p. 1-21, vii.
4. Rustgi V.K. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007, 42:513-521.
5. Center for Disease Control and Prevention (CDC) Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep 2013, 62(18):362-365.
6. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
7. Dienstag J.L., McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006, 130. 231-64; quiz 14-7.
8. Yee H.S., Currie S.L., Darling J.M., Wright T.L. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C Program office. Am J Gastroenterol 2006, 101:2360-2378.
9. Bacon B.R., Gordon S.C., Lawitz E., Marcellin P., Vierling J.M., Zeuzem S., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1207-1217.
10. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., Reddy K.R., Bzowej N.H., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011, 364:2405-2416.
11. Poordad F., McCone J., Bacon B.R., Bruno S., Manns M.P., Sulkowski M.S., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011, 364:1195-1206.
12. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364:2417-2428.
13. European Association for the Study of the Liver Electronic addressee. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2014, 60:392-420.
14. Ghany M.G., Nelson D.R., Strader D.B., Thomas D.L., Seeff L.B. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444. American Association for Study of Liver D.
15. Harrington P.R., Zeng W., Naeger L.K. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012, 55:1048-1057.
16. Liang T.J., Ghany M.G. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013, 368:1907-1917.
17. Beinhardt S., Rutter K., Stattermayer A.F., Ferenci P. Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus. Clin Infect Dis 2013, 56:118-122.
18. Pas S., Molenkamp R., Schinkel J., Rebers S., Copra C., Seven-Deniz S., et al. Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA. J Clin Microbiol 2013, 51:238-242.
19. Zitzer H., Heilek G., Truchon K., Susser S., Vermehren J., Sizmann D., et al. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV quantitative test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol 2013, 51:571-577.
20. Center for Disease Analysis HCV Global Prevalance, Genotype Distribution 2012, http://www.centerforda.com/map_leg.htm.
21. Huang Y., Dai Z., Barbacioru C., Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 2005, 65:7446-7454.
22. Balendiran G.K., Dabur R., Fraser D. The role of glutathione in cancer. Cell Biochem Funct 2004, 22:343-352.
23. Center for Disease Control and Prevention (CDC) Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Morb Mortal Wkly Rep 2012, 61.
24. Maasoumy B., Cobb B., Bremer B., Luk K., Halfon P., Aslam S., et al. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment Pharmacol Ther 2014, 39(1):85-92.
25. Peiffer K.H., Sarrazin C. The importance of HCV RNA measurement for tailoring treatment duration. Dig Liver Dis 2013, 45(Suppl. 5):S323-S331.
26. Jacobson I.M., Gordon S.C., Kowdley K.V., Yoshida E.M., Rodriguez-Torres M., Sulkowski M.S., et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013, 368:1867-1877.
27. Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
28. Zeuzem S., Berg T., Gane E., Ferenci P., Foster G.R., Fried M.W., et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a Phase IIb Trial. Gastroenterology 2014, 146(2):430-441.
29. Chevaliez S., Bouvier-Alias M., Rodriguez C., Soulier A., Poveda J.D., Pawlotsky J.M. The Cobas AmpliPrep/Cobas TaqMan HCV test, version 2.0, real-time PCR assay accurately quantifies hepatitis C virus genotype 4 RNA. J Clin Microbiol 2013, 51:1078-1082.